Corrigendum: 2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis

Adam D Kennedy; Kirk L Pappan; Taraka Donti; Mauricio R Delgado; Marwan Shinawi; Toni S Pearson; Seema R Lalani; William J Craigen; V Reid Sutton; Anne M Evans; Qin Sun; Lisa T Emrick; Sarah H Elsea

doi:10.3389/fnins.2019.01344

Corrigendum: 2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis

Front Neurosci. 2020 Jan 29:13:1344. doi: 10.3389/fnins.2019.01344. eCollection 2019.

Authors

Affiliations

¹ Metabolon, Inc., Morrisville, NC, United States.
² Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States.
³ Department of Neurology and Neurotherapeutics, Texas Scottish Rite Hospital for Children, The University of Texas Southwestern Medical Center, Dallas, TX, United States.
⁴ Department of Pediatrics, Washington University School of Medicine St. Louis, St. Louis, MO, United States.
⁵ Department of Neurology, Washington University School of Medicine St. Louis, St. Louis, MO, United States.
⁶ Department of Neurology, Baylor College of Medicine, Houston, TX, United States.

Abstract

[This corrects the article DOI: 10.3389/fnins.2019.00394.].

Keywords: 2-pyrrolidinone; 4-aminobutyrate aminotransferase deficiency; GABA; GABA-transaminase deficiency; inborn error of metabolism; neurometabolic; neurotransmitter; vigabatrin.

Publication types

Published Erratum